

# UC San Diego

## UC San Diego Previously Published Works

### Title

Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer

### Permalink

<https://escholarship.org/uc/item/8f49s99n>

### Journal

Breast Cancer Research, 26(1)

### ISSN

1465-5411

### Authors

Shatsky, Rebecca A  
Batra-Sharma, Hemali  
Helsten, Teresa  
[et al.](#)

### Publication Date

2024

### DOI

10.1186/s13058-024-01805-w

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

CORRECTION

Open Access



# Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer

Rebecca A. Shatsky<sup>1,2</sup>, Hemali Batra-Sharma<sup>1,2</sup>, Teresa Helsten<sup>1,2</sup>, Richard B. Schwab<sup>1,2</sup>, Emily I. Pittman<sup>1</sup>, Minya Pu<sup>1</sup>, Elizabeth Weihe<sup>4</sup>, Emanuela M. Ghia<sup>1,5</sup>, Laura Z. Rassenti<sup>1,5</sup>, Alfredo Molinolo<sup>1</sup>, Betty Cabrera<sup>6</sup>, James B. Breitmeyer<sup>7</sup>, George F. Widhopf II<sup>2,5</sup>, Karen Messer<sup>1,3</sup>, Catriona Jamieson<sup>1,2,6,8</sup>, Thomas J. Kipps<sup>1,5</sup> and Barbara A. Parker<sup>1,2\*</sup>

**Correction to: Shatsky et al. *Breast Cancer Research* (2024) 26:32**<https://doi.org/10.1186/s13058-024-01782-0>

The original article contained three typesetting errors. “Her2-negative” in the title should have been written as “HER2-negative”. Hence, the title should read: A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer, as shown in this Correction Article.

In the Background section of the original article, on page 2, paragraph 2, there was a

misspelling of “immuneodeficient”. The correct spelling is “immunodeficient.”

Also on page 2, in the section on Patient Selection, there was a misspelling of “HERer2”. The correct spelling is “HER2” as displayed throughout the manuscript.

The original article [1] has been updated.

Published online: 13 March 2024

## References

1. Shatsky RA, Batra-Sharma H, Helsten T, et al. A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer. *Breast Cancer Res.* 2024;26:32. <https://doi.org/10.1186/s13058-024-01782-0>.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at <https://doi.org/10.1186/s13058-024-01782-0>.

\*Correspondence:

Barbara A. Parker  
baparker@health.ucsd.edu

<sup>1</sup>Moores Cancer Center, University of California San Diego, 3855 Health Sciences Drive Mail Code 0987, La Jolla, San Diego, CA 92093, USA

<sup>2</sup>Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, USA

<sup>3</sup>Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, San Diego, CA, USA

<sup>4</sup>Department of Radiology, University of California San Diego, La Jolla, San Diego, CA, USA

<sup>5</sup>Center for Novel Therapeutics, University of California San Diego, La Jolla, San Diego, CA, USA

<sup>6</sup>University of California San Diego California Institute for Regenerative Medicine Alpha Clinic, La Jolla, San Diego, CA, USA

<sup>7</sup>Oncternal Therapeutics, Inc., San Diego, CA, USA

<sup>8</sup>Sanford Stem Cell Institute, University of California San Diego, La Jolla, San Diego, CA, USA



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.